Inhibikase Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Inhibikase Therapeutics CEO'su Milton Werner, Jun2010 tarihinde atandı, in görev süresi 14.42 yıldır. in toplam yıllık tazminatı $ 811.43K olup, şirket hissesi ve opsiyonları dahil olmak üzere 62.9% maaş ve 37.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.32% ine doğrudan sahiptir ve bu hisseler $ 1.79M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 10.3 yıl ve 3.9 yıldır.

Anahtar bilgiler

Milton Werner

İcra Kurulu Başkanı

US$811.4k

Toplam tazminat

CEO maaş yüzdesi	62.9%
CEO görev süresi	14.4yrs
CEO sahipliği	1.3%
Yönetim ortalama görev süresi	10.3yrs
Yönetim Kurulu ortalama görev süresi	3.9yrs

Son yönetim güncellemeleri

Recent updates

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Apr 06

CEO Tazminat Analizi

Milton Werner'un ücretlendirmesi Inhibikase Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$20m
Jun 30 2024	n/a	n/a	-US$18m
Mar 31 2024	n/a	n/a	-US$19m
Dec 31 2023	US$811k	US$510k	-US$19m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$744k	US$501k	-US$18m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$611k	US$455k	-US$15m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$7m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$961k	US$293k	-US$3m
Sep 30 2020	n/a	n/a	-US$2m
Jun 30 2020	n/a	n/a	-US$3m
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$385k	US$293k	-US$6m
Sep 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$4m
Dec 31 2018	US$535k	US$452k	-US$2m

Tazminat ve Piyasa: Milton 'ın toplam tazminatı ($USD 811.43K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 652.28K ).

Tazminat ve Kazançlar: Milton şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Milton Werner (60 yo)

14.4yrs

Görev süresi

US$811,429

Tazminat

Dr. Milton H. Werner, Ph D., serves as the Chief Executive Officer and President at Inhibikase Therapeutics, Inc. since June 2010. Prior to founding Inhibikase, From May 2007 until August 2008, Dr. Werner...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Milton Werner	CEO, President & Director	14.4yrs	US$811.43k	1.32% $ 1.8m
Garth Lees-Rolfe	Chief Financial Officer	less than a year	Veri yok	0% $ 0
Surendra Singh	Head of Chemistry	10.3yrs	Veri yok	Veri yok
Dan Williams	Controller	no data	Veri yok	Veri yok

10.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: IKT 'un yönetim ekibi deneyimli ve deneyimlidir ( 10.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Milton Werner	CEO, President & Director	14.4yrs	US$811.43k	1.32% $ 1.8m
Dennis Berman	Independent Director	3.9yrs	US$74.85k	0% $ 0
Kenneth Marek	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeffrey Kordower	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Pankaj Pasricha	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Roy Freeman	Independent Director	3.9yrs	US$65.85k	0% $ 0
Roberto Bellini	Chairman	less than a year	Veri yok	2.17% $ 2.9m
Robert Hauser	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Karl Kieburtz	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ted Dawson	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Valina Dawson	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

3.9yrs

Ortalama Görev Süresi

65.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IKT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.9 yıldır).

Inhibikase Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Inhibikase Therapeutics, Inc. Announces Board Changes

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

High number of new and inexperienced directors

Recent updates

New major risk - Negative shareholders equity

Third quarter 2024 earnings released: US$0.65 loss per share (vs US$0.86 loss in 3Q 2023)

New major risk - Shareholder dilution

Insufficient new directors

Inhibikase Therapeutics, Inc. announced that it has received $109.982165 million in funding from a group of investors

Inhibikase Therapeutics, Inc. announced that it expects to receive $109.982165 million in funding from a group of investors

Inhibikase Therapeutics, Inc. Announces Board Changes

First half 2024 earnings released: US$1.39 loss per share (vs US$2.08 loss in 1H 2023)

Inhibikase Therapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Inhibikase Therapeutics, Inc. Announces Expansion to Its Therapeutic Pipeline

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.8 million.

First quarter 2024 earnings released: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)

Inhibikase Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Inhibikase Therapeutics Announces Final Pre-Ind Meeting Outcomes for Ikt-001Pro as A Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New major risk - Market cap size

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Full year 2023 earnings: EPS misses analyst expectations

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders

Inhibikase Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.659255 million.

New major risk - Share price stability

Consensus revenue estimates increase by 44%

Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024

Inhibikase Therapeutics, Inc. Provides Update on Development Programs

Inhibikase Therapeutics, Inc. Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Third quarter 2023 earnings released: US$0.86 loss per share (vs US$1.07 loss in 3Q 2022)

Inhibikase Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

Inhibikase Therapeutics, Inc. Announces Development of Novel Formulation of Rampsvodetinib

Consensus revenue estimates increase by 178%, EPS downgraded

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of Ikt-001Pro

New major risk - Financial position

Second quarter 2023 earnings released: US$1.11 loss per share (vs US$1.10 loss in 2Q 2022)

Inhibikase Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Inhibikase Therapeutics Announces 1-For-6 Reverse Stock Split to Bring the Company into Compliance with Nasdaq's Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Inhibikase Therapeutics, Inc. Initiates Medical and Patient Awareness Campaign for Its Phase 2 '201' Trial Evaluating It-148009 in Parkinson's Disease

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022)

Inhibikase Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 23, 2023

Inhibikase Therapeutics, Inc. announced that it expects to receive $4.199512 million in funding

Inhibikase Therapeutics Announces Publication Demonstrating Potential for C-Abl as A Key Therapeutic Target in Parkinson's Disease and Related Disorders

Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?

Inhibikase Therapeutics, Inc. Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics, Inc. Provides Update to FDA Clinical Hold of IkT-148009 Programs

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.18 loss in 3Q 2021)

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Inhibikase Therapeutics, Inc Announces FDA Clinical Hold on IkT-148009 Programs

High number of new and inexperienced directors

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc. Announces Executive Changes

Inhibikase Therapeutics, Inc Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia

Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia

Inhibikase Therapeutics, Inc. Doses First Patient in Its Phase 2a '201' Clinical Trial of IKT-148009 to Treat Parkinson's Disease

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2021)

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Inhibikase Therapeutics, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Inhibikase Therapeutics Receives a Letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Inhibikase Therapeutics, Inc. Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.26 loss in 1Q 2021)

Inhibikase Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

Inhibikase Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation

Full year 2021 earnings released: US$0.81 loss per share (vs US$0.35 loss in FY 2020)

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.082 loss in 3Q 2020)